Jiyeongmi Disease Control Agency Director Meets Sanofi... Discusses Vaccine Supply and R&D

Jiyoungmi, Commissioner of the Korea Disease Control and Prevention Agency, met on the afternoon of the 5th with Thomas Trionf, Head of Sanofi Vaccine Division, and Pascal Robin, CEO of Sanofi Korea, to discuss the stable supply of vaccines for the national immunization program and the progress of research and development cooperation.

Jiyoungmi, Director of the Korea Disease Control and Prevention Agency.

During the meeting, Sanofi introduced its vaccines under development or in use, including the 6-valent combination vaccine (DTap-IPV-Hib-HepB), high-dose influenza vaccine, respiratory syncytial virus preventive antibody agent, and COVID-19 booster vaccines, as well as the status of research and development cooperation with domestic manufacturers in the field of pneumococcal vaccine development.

Trionf stated, "Sanofi is committed to recognizing the importance of vaccination for disease prevention throughout the entire lifespan and improving patient accessibility," adding, "We will continue to actively participate in South Korea's national immunization program and strive to ensure stable vaccine supply as well as the development and production of vaccines with high efficacy and safety."

Commissioner Ji said, "Manufacturers play a significant role as partners in the national immunization program," and added, "We hope that collaboration with domestic manufacturers for the development and supply of safe and reasonably priced vaccines, as well as for new vaccine development, will continue for the healthy lives of our citizens."